BNP/CALL/ASTRAZENECA/11000/0.1/20.12.24 Stock

DE000PC3BU25

Market Closed - Boerse Frankfurt Warrants 11:20:57 2024-05-31 EDT
2.12 ^EUR	+6.53%

1 month	+4.95%
3 months	+194.44%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ASTRAZENECA PLC

Chart BNP/CALL/ASTRAZENECA/11000/0.1/20.12.24

Latest news about ASTRAZENECA PLC

Health Care Stocks Climb On Drug News -- Health Care Roundup	05-31	DJ
Fusion Pharmaceuticals Gets Court Order Approving AstraZeneca Deal	05-31	MT
News Highlights: Top Company News of the Day - Friday at 1 PM ET	05-31	DJ
News Highlights : Top Company News of the Day - Friday at 11 AM ET	05-31	DJ

More news

Quotes 5-day view

Date	Price	Change
24-05-31	2.12	+6.53%
24-05-30	1.99	+5.85%
24-05-29	1.88	-4.08%
24-05-28	1.96	-12.89%
24-05-24	2.25	-3.43%

Real-time Boerse Frankfurt Warrants

Last update May 31, 2024 at 11:20 am

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	ASTRAZENECA PLC
Issuer	BNP Paribas
WKN	PC3BU2
ISIN	DE000PC3BU25
Date issued	2024-01-16
Strike	11,000 p
Maturity	2024-12-20 (202 Days)
Parity	10 : 1
Emission price	1.12 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	2.35 €
Lowest since issue	0.43 €
Delta	0.79x
Omega	5.349
Premium	4.88x
Gearing	6.75x
Moneyness	1.110
Difference Strike	-1,190 p
Difference Strike %	-10.82%
Spread	0.01 €
Spread %	0.47%
Theoretical value	2.125
Implied Volatility	24.63 %
Total Loss Probability	26.31 %
Intrinsic value	1.425
Present value	0.7001
Break even	12,810.51 €
Theta	-0.02x
Vega	0.03x
Rho	0.05x

Company Profile

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

More about the company